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Introduction: Anti-neutrophil cytoplasmic antibody-associated vasculitis has been associated with many drugs and
it is a relatively rare side effect of the antihypertensive drug hydralazine. The diagnosis and management of patients
who have anti-neutrophil cytoplasmic antibody-associated vasculitis may be challenging because of its relative
infrequency, variability of clinical expression and changing nomenclature. The spectrum of anti-neutrophil
cytoplasmic antibody-associated vasculitis is wide and can be fatal. This case documents a 62-year-old woman who
presented with hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis with a puzzling
cutaneous rash.
Case presentation: We report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated
vasculitis in a 62-year-old Caucasian woman who presented with a vasculitic syndrome with a sore throat, mouth
ulcers and otalgia after several months of constitutional symptoms. She then proceeded to develop a rash over her
right lower limb. Clinically, the rash had features to suggest Sweet’s syndrome, but also had some appearances
consistent with embolic phenomena and did not have the appearance of palpable purpure usually associated with
cutaneous vasculitis. Differential diagnoses were hydralazine-associated Sweet’s syndrome, streptococcal-induced
cutaneous eruption or an unrelated contact dermatitis. A midstream urine sample detected glomerular blood cells
in the setting of anti-neutrophil cytoplasmic antibody-positive renal vasculitis and Streptococcus pyogenes
bacteremia. A renal biopsy revealed a pauci-immune, focally necrotizing glomerulonephritis with small crescents.
Her skin biopsy revealed a heavy neutrophil infiltrate involving the full thickness of the dermis with no evidence of
a leucocytoclastic vasculitis, but was non-specific. She was initially commenced on intravenous lincomycin for her
bloodstream infection and subsequently commenced on immunosuppression after cessation of hydralazine. The
patient was subsequently discharged from hospital after a rapid clinical improvement.
Conclusion: Hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis is a rare adverse
effect and can present with a severe vasculitic syndrome with multiple organ involvement. Features of this
association include the presence of high titres of anti-myeloperoxidase-anti-neutrophil cytoplasmic antibody with
multi-antigenicity, positive anti-histone antibodies and the lack of immunoglobulin and complement deposition
histopathogically. A rash that is characteristic of Sweet’s syndrome has also been described as an association.
Prompt cessation of hydralazine may be sufficient to reverse disease activity but immunosuppression may be
needed for definite treatment.
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Figure 2 Photomicrograph of the skin biopsy with a
hematoxylin and eosin stain ×100 showing a heavy neutrophil
infiltrate involving the full thickness of the dermis with no
evidence of a leucocytoclastic vasculitis.
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Hydralazine is a vasodilator that is often used as an
adjunctive agent in the treatment of hypertension. Anti-
neutrophil cytoplasmic antibody-associated vasculitis has
been associated with many drugs such as allopurinol, sulfa-
salazine and propylthiouracil and is a relatively rare side
effect of hydralazine. The etiology of ANCA-associated
vasculitis (AAV) is not always clear and this association is
less well recognized compared to drug-induced lupus
which is well documented in the literature [1]. The diagno-
sis and management of patients may be challenging
because of its relative infrequency, variability of clinical
expression and changing nomenclature. The spectrum of
AAV can range from cutaneous rashes and petechiae
or single organ involvement to fatal multi-organ involve-
ment with deaths commonly from massive pulmonary
hemorrhage. A latency of several years can occur before
the development of vasculitis with a variable delay in the
full clinical manifestations [2] therefore posing a challenge
for clinicians to achieve clear diagnoses and treatment
strategies. This case documents a 65-year-old woman who
presented with a diagnostic dilemma after developing a
lower limb rash and a sore throat with Streptococcus pyo-
genes bacteremia and highlights the need for early recog-
nition to enable timely cessation of the offending drug or
drugs and commencement of appropriate therapy.Figure 1 Photograph of the right ankle and foot showing an
erythematous papular rash with ulcerations on presentation.Case presentation
A 62-year-old Caucasian woman of Anglo-Saxon back-
ground with resistant hypertension developed a sore
throat, mouth ulcers and otalgia after several months of
constitutional symptoms consisting of lethargy, night
sweats and significant weight loss. She then proceeded
to develop a rash over her right lower limb. Her past
medical history consisted of Hashimoto’s thyroiditis,
rheumatic heart disease, hyperlipidemia and recurrent
deep venous thromboses due to the factor V Leiden mu-
tation for which she was on lifelong warfarin. Other
medications taken regularly consisted of: hydralazine
100mg in the morning, 50mg at night which she had
taken for three years; perindopril 10mg daily; metoprolol
50mg twice daily; clonidine 50mg twice daily; thyroxine
50mcg and 25mcg on alternate days; and rosuvastatin
5mg at night. An examination revealed hypertension
(blood pressure 160/70mmHg), a pansystolic murmur,
an aphthous ulcer at the base of her tongue and a rash
over her right ankle and foot (Figure 1). Baseline blood
tests revealed a leucocytosis of 19.2×109/L with a neu-
trophilia of 16.85×109/L and raised erythrocyte sedimen-
tation rate of 123mm/hour. Blood cultures taken on
admission yielded S. pyogenes and she was immediately
treated with intravenous lincomycin because of a previ-
ous penicillin allergy. A transesophageal echo was
carried out which excluded infectious endocarditis.
Blood tests revealed impaired kidney function, a serum
creatinine concentration of 102μmol/L, and an estimated
glomerular filtration rate (eGFR) of 48mL/min/1.73m2
which is at her baseline renal function. Her urine
revealed microscopic hematuria with 360×106/L red
blood cells without any urinary tract infection and she
only had mild proteinuria of 460mg/L, and a protein:
Figure 3 Photomicrograph of the renal biopsy with a
hematoxylin and eosin stain ×400 magnification showing a
pauci-immune, focal necrotizing glomerulonephritis with one
small crescent consistent with anti-neutrophil cytoplasmic
antibody-associated vasculitis. Red cell casts are present. There is
an interstitial infiltrate of lymphocytes, macrophages and eosinophils
which involves some tubules. Immunofluorescence staining revealed
mild mesangial deposition of immunoglobulin M and traces of
mesangial C3.
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an anti-nuclear antibody >2560, double-stranded deoxy-
ribonucleic acid (DNA) antibody elevated at 14 (<7), peri-
nuclear (P)-ANCA >2560 and anti-myeloperoxidase
(MPO) antibody >100μ/mL with positive anti-histone
antibodies. Because of glomerular blood cells in a repeat
midstream urine sample taken on day 17 after presenta-
tion, acute kidney injury with a serum creatinine of now
195μmol/L, eGFR 23mL/min/1.73m2, worsening protein-
uria (810mg/L), normal serum complement levels and
high titres of vasculitic markers, a drug-associated ANCATable 1 Hydralazine-associated anti-neutrophil cytoplasmic a
Short and Lockwood (1995) [1
Number of patients 10
Age range (years) 55–76
Females (%), female/total patients 70 (7/10)
Hydralazine dose range (mg/day) 50–150
Duration of drug exposure (months) 36–156
Patients with renal involvement 10
Patients with cutaneous involvement 4
Patients with pulmonary involvement 2




Abbreviations: ANCA, anti-neutrophil cytoplasmic antibodies; GN, glomerulonephrit
* Authors estimated number from data available in the literature.vasculitis was suspected. However, due to the temporal re-
lation of two weeks between a streptococcal bloodstream
infection and the development of an acute nephritic syn-
drome, post-streptococcal glomerulonephritis was also
considered. The associated skin rash (Figures 1 and 2) did
not have a clear role in her presentation but was initially
thought to be early Sweet’s syndrome associated with a
drug-associated vasculitis. Hydralazine was withdrawn
and the patient underwent a transjugular renal biopsy to
confirm the diagnosis (Figure 3). The patient was com-
menced on treatment consisting of three intravenous
pulses of methylprednisolone followed by high dose
prednisolone and mycophenolate mofetil 1g twice daily.
Her urine immediately became clear and her skin rash
resolved quickly when the mycophenolate mofetil was
started and her renal function improved, suggesting that
the cause of the rash was immunological in etiology.
Serum creatinine concentration on discharge (day 35) was
144μmol/L. The patient attended an out-patient follow-up
clinic a fortnight and then a month later to commence
prednisone tapering as per the European Vasculitis Study
Group protocol and to continue her mycophenolate mofe-
til for six months. A repeat serum creatinine concentra-
tion was 96μmol/L and anti-MPO was 16u/mL.
Discussion
Hydralazine-induced ANCA vasculitis is rare and not
the first diagnosis that came to mind with our patient
who displayed a wide spectrum of disease of drug-
induced AAV with severe renal and possible cutaneous
manifestations requiring immunosuppression. The pre-
sence of high titres of P-ANCA and anti-MPO with
multi-antigenicity, the positive anti-histone antibodies
and the lack of immunoglobulin and complement depo-
sition histopathogically are features that have beenntibody-positive pauci-immune glomerulonephritis
0] Choi et al. (2000) [1] Yokogawa and Vivino (2009) [9]
10 68
45–81 60–67
70 (7/10) 59 (40/68)
75–200 50–300








is; MPO, myeloperoxidase antibodies; NR, not reported.
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ther than with drug-induced lupus or with primary vas-
culitis. Therefore we strongly suspect this to be an
adverse effect of hydralazine. The histology for the cuta-
neous rash was not classical for Sweet’s syndrome which
would involve a denser neutrophilic infiltration in the
dermis; however, the cutaneous rash did have some simi-
larities with this syndrome: a neutrophilic infiltration on
histology, a neutrophilia on presentation, fever and a
tender papular skin rash. This rash was also in the
setting of a S. pyogenes bacteremia which could have
resulted in the skin rash. The differential diagnoses for
the cutaneous rash were hydralazine associated with
early Sweet’s syndrome as described with carbamazepine
in the literature [4], cutaneous vasculitis [5], erythro-
derma, streptococcal-induced cutaneous eruption from
hematogenous spread, or an unrelated cause such as a
contact dermatitis or early cellulitis.
Risk factors that have been identified predisposing to
hydralazine-related AAV include a cumulative dose of
more than 100g, female sex, and history of thyroid
disease [6] as seen in our patient. Other risk factors in-
clude the human leukocyte antigen (HLA)-DR4 geno-
type, slow hepatic acetylation and the null gene for C4
[7]. The mechanism or mechanisms for hydralazine-
induced AAV is not fully understood but might be
multifactorial. Hypotheses of immune system activation
by drug metabolites with autoimmunity towards neutro-
phil proteins (including elastase and lactoferrin) and
upregulation of ANCA antigens have been suggested [5].
A review of the literature revealed 68 patients with
hydralazine-induced vasculitis [1,8,9] and five cases with
ANCA-positive hydralazine-associated immune complex-
mediated renal vasculitis with cutaneous involvement.
However, there were no cases of ANCA-positive hydrala-
zine-associated renal vasculitis with pauci-immune glome-
rulonephritis and a vasculitic cutaneous rash or Sweet’s
syndrome (see Table 1). The hydralazine dosage ranged
from 50 to 300mg per day, and the treatment duration
varied from 0.73 to 120 months. Almost all the patients
from the literature were positive for MPO antibodies and
all of the patients with anti-histone antibodies checked
had positive results. Our patient did not have clear cuta-
neous involvement with her presentation and the afore-
mentioned renal–cutaneous association syndrome is yet
to be published in the literature to date.
Conclusion
Hydralazine-induced ANCA-positive renal vasculitis is a
rare adverse effect and can present with a severe vascu-
litic syndrome with multiple organ involvement. Early
diagnosis and recognition of the clinical patterns of dis-
ease will be essential for prompt treatment. Timely ces-
sation of hydralazine may be sufficient to reverse diseaseactivity to prevent progression of disease towards end-
stage renal failure [11]. However, a short course of
immunosuppressive therapy and monitoring of serum
ANCA may be all that is required without the need for
long-term maintenance. Caution should be displayed
when using this drug and it may be prudent to refrain
from prescribing it to patients with a past history of
autoimmune disease and to regularly check for urinary
glomerular blood cells.
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